Press releases
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
- AbCellera Announces Resignation of Board Member
- AbCellera to Present at Upcoming Investor Conferences in March
- AbCellera Reports Full Year 2023 Business Results
More ▼
Key statistics
On Friday, Abcellera Biologics Inc (8QQ:DEU) closed at 3.80, 14.47% above the 52 week low of 3.32 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.58 |
---|---|
High | 3.80 |
Low | 3.53 |
Bid | 3.73 |
Offer | 3.77 |
Previous close | 3.59 |
Average volume | 977.40 |
---|---|
Shares outstanding | 292.78m |
Free float | 210.50m |
P/E (TTM) | -- |
Market cap | 1.18bn USD |
EPS (TTM) | -0.5062 USD |
Data delayed at least 15 minutes, as of May 03 2024.
More ▼